Eupraxia Pharmaceuticals

EPRX

Biotechnology · Healthcare

Also trades as: EPRX.TO

Price

$6.73

-0.03 (-0.44%)

Market Cap

$225.3M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+180.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 14.2M (2021) → 40.0M (2025)

Winston Score History

The full picture

Eupraxia Pharmaceuticals is a Canadian clinical-stage biotechnology company focused on developing injectable drugs that treat pain and inflammation. Its lead product, EP-104IAR, is a longer-lasting form of a steroid called fluticasone propionate, designed to be injected directly into joints to relieve pain from conditions like osteoarthritis. The main customers would be patients and physicians dealing with chronic joint pain, a very large and underserved medical market.

Eupraxia does not yet sell any products, so it currently earns no revenue. The company funds its operations through equity financing and is based in Victoria, British Columbia, Canada. Its core competitive idea is a proprietary drug-delivery technology that aims to make existing medicines last longer inside the body, potentially reducing how often patients need injections. The biggest risk the company faces is clinical and regulatory — EP-104IAR must still successfully complete clinical trials and receive approval from regulators like the FDA before it can generate any sales.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+4.2% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$30M/ year

↑ Rising (+84% vs prior year)

R&D investment increasing — building for the future

Insider Activity

22.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~3 years

$133M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$133M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-43.2%

Weak — -43.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial